An anti-COVID-19 therapeutic drug developed by DRDO called drug2-deoxy-D-glucose (2-DG) has been given emergency approval by the Drug Controller General of India (DCGI) for Coronavirus patients in the country. The Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRDO), has developed the drug, in collaboration with Dr Reddy’s Laboratories, Hyderabad.
Buy Prime Test Series for all Banking, SSC, Insurance & other exams
In 2-DG arm, significantly higher proportion of patients improved symptomatically and became free from supplemental oxygen dependence (42% vs 31%) by day-3 in comparison to SOC, indicating an early relief from oxygen therapy/dependence. The drug comes in the form of a powder in a sachet & is supposed to be dissolved in water.
Important takeaways for all competitive exams:
Lithium, a crucial component in the production of batteries for electric vehicles, electronics, and energy…
India Ratings and Research have revised upward their GDP growth estimate for FY25 to 7.1%,…
The Spanish football giants, Real Madrid, have etched another remarkable achievement in their illustrious history…
Indian-origin astronaut Sunita Williams, alongside colleague Butch Wilmore, is embarking on her third space mission…
West Bengal, a state rich in history and cultural heritage, has seen a succession of…
In a significant political development, José Raúl Mulino has emerged victorious in Panama's presidential election,…